| Recruiting | A Phase 1B/2A Trial of NADUNOLIMAB in Combination With Azacitidine (With/Without Venetoclax) in Patients With NCT06548230 | M.D. Anderson Cancer Center | Phase 1 / Phase 2 |
| Recruiting | Cord Blood Transplant in Adults With Blood Cancers NCT05884333 | Memorial Sloan Kettering Cancer Center | Phase 2 |
| Unknown | MAX-40279 in Subjects With Acute Myelogenous Leukemia (AML) NCT03412292 | Maxinovel Pty., Ltd. | Phase 1 |
| Unknown | Non-interventional, Long-term Follow-up of Subjects Who Completed ApoGraft-01 Study NCT03260101 | Cellect Biotechnology | — |
| Terminated | A Study of the Effect of Blood Stem Cell Transplant After Chemotherapy Alone in Patients With Fanconi Anemia NCT03600909 | Memorial Sloan Kettering Cancer Center | Phase 2 |
| Completed | Relapse Prophylaxis With N-803 for AML and MDS Pts Following Allo HSCT NCT02989844 | Masonic Cancer Center, University of Minnesota | Phase 2 |
| Completed | Stem Cell Transplantation With NiCord® (Omidubicel) vs Standard UCB in Patients With Leukemia, Lymphoma, and M NCT02730299 | Gamida Cell ltd | Phase 3 |
| Completed | HLA-Mismatched Unrelated Donor Bone Marrow Transplantation With Post-Transplantation Cyclophosphamide NCT02793544 | Center for International Blood and Marrow Transplant Research | Phase 2 |
| Unknown | Phase I Study of an Oncofetal Antigen Multi-Peptide Immunotherapy in Subjects With Hematologic Cancer NCT02240537 | Benovus Bio, Inc. | Phase 1 |
| Completed | Ultra-Low Dose IL-2 Therapy as GVHD Prophylaxis in Haploidentical Allogeneic Stem Cell Transplantation NCT02226861 | National Heart, Lung, and Blood Institute (NHLBI) | Phase 1 |
| Terminated | A Safety and Tolerability Study of CDX-301 With or Without Plerixafor for Stem Cell Mobilization in Matched Re NCT02200380 | Celldex Therapeutics | Phase 2 |
| Recruiting | HSCT for Patients With Fanconi Anemia Using Risk-Adjusted Chemotherapy NCT02143830 | Children's Hospital Medical Center, Cincinnati | Phase 2 |
| Completed | Red Cell Transfusion Goals in Patients With Acute Leukemias NCT02086773 | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | Phase 1 |
| Completed | Maintenance Low Dose 5'-Azacitidine Post T Cell Depleted Allogeneic Stem Cell Transplantation for Patients Wit NCT01995578 | Memorial Sloan Kettering Cancer Center | Phase 2 |
| Completed | IL-15 Super Agonist ALT-803 to Treat Relapse Of Hematologic Malignancy After Allogeneic SCT NCT01885897 | Masonic Cancer Center, University of Minnesota | Phase 1 / Phase 2 |
| Active Not Recruiting | CD34+ (Malignant) Stem Cell Selection for Patients Receiving Allogenic Stem Cell Transplant NCT02061800 | Diane George | Phase 1 / Phase 2 |
| Terminated | Omacetaxine for Consolidation and Maintenance NCT01873495 | Emory University | Phase 2 |
| Unknown | Vidaza and Valproic Acid Post Allogeneic Transplant for High Risk AML and MDS NCT02124174 | Patrick Stiff | Phase 2 |
| Completed | Single Treatment With FT1050 of an Ex-vivo Modulated Umbilical Cord Blood Unit NCT01527838 | Fate Therapeutics | Phase 1 |
| Terminated | Study of MK-8242 Alone and in Combination With Cytarabine in Participants With Acute Myelogenous Leukemia (P07 NCT01451437 | Merck Sharp & Dohme LLC | Phase 1 |
| Terminated | Study of the Safety, Tolerability, Pharmacokinetics and Pharmacodynamic Properties of Oral AT-406 in Combinati NCT01265199 | Ascenta Therapeutics | Phase 1 |
| Completed | Pilot Study Evaluating Safety & Efficacy of DCBT: NiCord® & UNM CBU to Patients With Hematological Malignancie NCT01221857 | Gamida Cell ltd | Phase 1 / Phase 2 |
| Terminated | Eltrombopag in Elderly Acute Myelogenous Leukemia (AML) NCT01113502 | Abramson Cancer Center at Penn Medicine | Phase 1 / Phase 2 |
| Withdrawn | A Randomized Study of Epigenetic Priming Using Decitabine With Front Line Induction Chemotherapy Compared With NCT00943553 | Eisai Inc. | Phase 2 |
| Terminated | Haploidentical Allogeneic Transplant With Post-transplant Infusion of Regulatory T-cells NCT01050764 | Everett Meyer | Phase 1 / Phase 2 |
| Completed | Unrelated Umbilical Cord Blood (UBC)Transplantation NCT01768845 | West Virginia University | N/A |
| Terminated | Safety, Tolerability, and Pharmacokinetic/Pharmacodynamic Study of KW-2449 in Acute Myelogenous Leukemia (AML) NCT00779480 | Kyowa Kirin Co., Ltd. | Phase 1 |
| Completed | Safety, Pharmacokinetics, and Pharmacodynamics of Oral Azacitidine in Subjects With Myelodysplastic Syndromes, NCT00528983 | Celgene | Phase 1 |
| Terminated | A Phase I Study of WT1 Peptides to Induce Anti-Leukemia Immune Responses Following Transplantation NCT00672152 | Michael Morse, MD | Phase 1 |
| Completed | Thymoglobulin to Prevent Acute Graft vs. Host Disease (GvHD) in Patients With Acute Lymphocytic Leukemia (ALL) NCT00088543 | Genzyme, a Sanofi Company | N/A |
| Approved For Marketing | Expanded Access for CC-486 NCT03723135 | Celgene | — |